131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status (Q33652433)

28 July 2017

1 reference

title

131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status (English)

1 reference

6 May 2020

1 reference

S Tepmongkol

1

1 reference

PubMed ID

10358701

6 May 2020

S Heyman

series ordinal

2

1 reference

PubMed ID

10358701

6 May 2020

language of work or name

English

0 references

publication date

1 June 1999

1 reference

Medical and Pediatric Oncology

28 July 2017

1 reference

6 May 2020

32

1 reference

28 July 2017

6

1 reference

28 July 2017

427-31; discussion 432

1 reference

Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry

28 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

Scintigraphic Localization of Pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

Radionuclide therapy revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

Therapeutic use of 131I-metaiodobenzylguanidine (MIBG) in neuroblastoma: a phase II study in nine patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

Treatment of neuroblastoma with metaiodobenzylguanidine: results and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceutical m-iodo-benzylguanidine in SK-N-SH neuroblastoma and PC-12 pheochromocytoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

The curability of tumours of differing size by targeted radiotherapy using 131I or 90Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

Implications of the uptake of 131I-radiolabelled meta-iodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

Role of 131I-metaiodobenzylguanidine in the treatment of neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131i] metaiodobenzylguanidine: Implications for the targeted radiotherapy of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

Multi-modality megatherapy with [131I]metaiodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: Feasibility study of a new strategy for advanced neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C427%3A%3AAID-MPO6%3E3.0.CO%3B2-T

10.1002/(SICI)1096-911X(199906)32:6<427::AID-MPO6>3.0.CO;2-T

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10358701